Our focus is on the following：neuroscience, oncology, cardiovascular, metabolism and autoimmunity. With a holistic view of treatment, we aim to gain a deeper understanding of pathogenesis of chronic and complex diseases, providing early diagnosis and treatment methods supported by the role of brain-gut axis in mechanisms of action.
GV-971 has a unique mechanism of action targeting brain-gut axis provides a scientific basis for deeper understanding of the characteristic clinical efficacy of Oligomannate. Click here to find more information.
R&D is at the heart of our business. For more than 20 years, Green Valley has been accumulated profound expertise and practice in the area of carbohydrate drugs innovation. The company has always embraced considerable investment on medical innovation every year, building the cutting-edge carbohydrate compound library and the drug candidates screening platform. The R&D team has screened out over 300 carbohydrate compounds with drug activity from thousands of plants, microorganisms, and marine organisms. We now have the world's leading R&D pipeline for carbohydrate drug products with more than 20 pre-clinical candidate compounds and 2 candidate drugs under phase II clinical research. Our R&D center will be located to Shanghai Zhangjiang Science City in the near future, equipped with world-class facilities, including a state-of-the-art carbohydrate chemistry center, a glycobiology center, an advanced carbohydrate drug in vivo screening center and modern executive offices with a total capacity of 3000 people.
Green Valley has established state-of-the-art manufacturing sites for carbohydrate drug products. The company has successfully overcome technology difficulties for carbohydrate drugs analysis and got a good command of core techniques for quality control.